Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Lipocine Inc.
  6. News
  7. Summary
    LPCN   US53630X1046

LIPOCINE INC.

(LPCN)
  Report
Delayed Quote. Delayed Nasdaq - 01/25 04:00:00 pm
0.9383 USD   +2.32%
01/21Lipocine Chief Financial Officer is Retiring
MT
01/21LIPOCINE INC. : Change in Directors or Principal Officers (form 8-K)
AQ
01/21Lipocine Inc. Announces Executive Changes
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Lipocine : Ladenburg Thalmann Adjusts Lipocine's Price Target to $2.50 From $3, Maintains Buy Rating

05/27/2021 | 02:23pm EST


ę MT Newswires 2021
All news about LIPOCINE INC.
01/21Lipocine Chief Financial Officer is Retiring
MT
01/21LIPOCINE INC. : Change in Directors or Principal Officers (form 8-K)
AQ
01/21Lipocine Inc. Announces Executive Changes
CI
01/21Lipocine Inc. Announces CFO Changes
CI
01/14LIPOCINE INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stan..
AQ
01/05Lipocine to Present Clinical Data on LPCN 1144 at 2022 NASH-TAG Conference
PR
01/04LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021LIPOCINE : ANNOUNCES patient dosed in its Phase 2 Study with LPCN 1148 for management of l..
PU
2021LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Lipocine Commences Dosing in Phase 2 Study of Liver Cirrhosis Drug
MT
More news
Analyst Recommendations on LIPOCINE INC.
More recommendations
Financials (USD)
Sales 2021 3,75 M - -
Net income 2021 -14,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,86x
Yield 2021 -
Capitalization 82,8 M 82,8 M -
Capi. / Sales 2021 22,1x
Capi. / Sales 2022 13,5x
Nbr of Employees 13
Free-Float 97,5%
Chart LIPOCINE INC.
Duration : Period :
Lipocine Inc. Technical Analysis Chart | LPCN | US53630X1046 | MarketScreener
Technical analysis trends LIPOCINE INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 0,94 $
Average target price 3,75 $
Spread / Average Target 300%
EPS Revisions
Managers and Directors
Mahesh V. Patel President, Chief Executive Officer & Director
Morgan R. Brown Chief Financial Officer & Executive Vice President
Anthony DelConte Chief Medical Director
Richard Dana Ono Independent Director
Stephen Anthony Hill Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LIPOCINE INC.-5.33%81
GILEAD SCIENCES, INC.-5.56%86 013
REGENERON PHARMACEUTICALS-1.60%64 979
VERTEX PHARMACEUTICALS4.59%58 397
WUXI APPTEC CO., LTD.-7.49%51 604
BIONTECH SE-41.44%36 465